

Date	Report / Update	Report Price (₹)	Buy Range (₹)	Target Price (₹)
14-Nov-25	Quick Insight	1616	1580 – 1620	1910 – 1950



Q3FY26 result update

The company delivered a strong Q3FY26 performance, with revenue of ₹815crs, up 24% YoY and 4% QoQ (19% in constant currency). EBITDA increased 40.4% YoY and 3.6% QoQ to ₹281crs, with margins expanding to ~35%. Reported PAT increased 41% YoY to ₹183crs, while adjusted PAT (excluding non-cash items) stood at ₹215crs, up 48% YoY. Q3FY26 result reflects continued profitable performance driven by operating leverage, increased technology adoption, and disciplined cost management, alongside steady expansion across existing and new client relationships.

Concall Highlights

- The management said that the company's core business is to eliminate non-core "chore tasks" for US healthcare providers, enabling them to focus on patient care. The total addressable market for these tasks is estimated at USD 260bn, of which only USD 34bn is currently outsourced and is growing at ~12% annually. The management further added that since IKS is growing faster than this outsourcing market, it is gaining market share in the outsourced healthcare services segment.
- The Management said that AI platforms are seen as a positive enabler rather than a threat, as IKS is indifferent to the underlying technology and is focused on removing tasks faster and at lower cost, irrespective of how the solutions are developed.
- The integration of the AQuity acquisition is largely complete with margin targets achieved faster than expected. Management stated that the remaining focus is on cross-selling into AQuity's health system clients, supported by a realignment of the go-to-market strategy toward large health systems (USD >5 bn in revenue). Management highlighted that early traction is visible and believes the integration is now in its final innings, while the pruning of AQuity's long-tail customers is ongoing and expected to conclude over the next few quarters.
- On margins front, the management indicated that IKS has largely reached its target EBITDA margin range of early-to-mid 30%. While automation and operating leverage continue to support efficiency gains, incremental benefits are expected to be reinvested into R&D, sales, and platform expansion. Consequently, management does not expect meaningful structural margin expansion from current levels, with future earnings growth likely to remain primarily revenue-led.
- Q3FY26 results included two one-off items an immaterial impact from labour code changes and a one-time non-cash write-off of ₹12.7crs related to loan refinancing, following the reduction of the term loan from USD 146mn to USD 50mn. Net debt declined further to ₹322crs (~USD 35mn).
- The company successfully executed four deal wins during Q3FY26. The management highlighted that the two unnamed deals are expected to start contributing from Q4FY26. The StrideCare engagement is expected to begin generating revenue from Q1FY27, with full go-live targeted by Q2FY27, while the Femwell deal, covering over 800 providers, will be rolled out in a phased manner over Q1–Q3FY27. In the case of StrideCare, management noted that nearly 90% of the scope replaces in-house operations rather than third-party vendors, with IKS also replacing part of the existing technology setup and significantly reducing doctors' administrative burden. Overall, management reiterated that 85–90% of incremental growth is expected to come from expansion within existing clients, rather than from new customer additions.

Important Data

Nifty	25,935.15
Sensex	84,273.92
Key Stock Data	
Close*	₹1,757.90
Market Cap (₹ bn)	₹294.77
52W High/Low	₹1,929/1,237
BSE Code	544309
NSE Code	IKS
Bloomberg Code	IKS:IN

Close* as on 10th February 2026

Shareholding Pattern (%)	Jun'25	Sep'25	Dec'25
Promoter	63.72%	63.72%	63.72%
DILs	6.50%	7.02%	7.56%
FILs	4.33%	4.89%	6.06%
Public & Others	25.45%	24.36%	22.66%

Financials

Particulars	FY24	FY25	FY26E	FY27E	FY28E
Revenue	1818	2664	3164	3474	3891
EBITDA	521	770	1,068	1,146	1,284
EBITDA Margin (%)	29%	29%	34%	33%	33%
Net Profit	371	487	704	763	872
PAT Margin	20%	18%	22%	22%	22%
EPS (₹)	22.2	28.6	41.4	44.8	51.2
RoE (%)	32%	27%	28%	23%	21%
P/E (x)	75.8	58.7	40.5	37.4	32.8
EV/EBITDA (x)	55.9	37.6	27.0	25.2	22.5
Debt/ equity	1.26	0.42	0.12	0.09	0.07

Source: Company Data, Way2Wealth

Relative Performance

Absolute Return (%)	1Yr	3Yr	5Yr
IKS	4%	-7%	-7%
Nifty50	11%	45%	72%
Sensex	9%	39%	64%

Source: Company, Way2Wealth

Rupali Singh

rupalisingh@way2wealth.com

91-22-4019 2907

Outlook and valuation

- Going forward, the company's "land and expand" strategy is driving platform adoption, especially among mid-sized and independent medical groups. It is expected to reshape the client mix over the next 2-3 years. With more than 80% of growth projected to come from existing customers and 85-90% of revenue from repeat business, IKS is well-positioned to deliver FY25-28E revenue, EBITDA, and PAT CAGR of 13%, 19%, and 21%, respectively, supported by margin expansion to 33%.
- **We assign a Hold rating on IKS Health**, supported by strong revenue visibility, scalable tech-led operations, and high client retention. At the current market price, the stock trades at 33x FY28E EPS of ₹51 and 23x EV/EBITDA, which appears reasonable compared to peers in the healthcare services and healthcare IT space.

Quarterly Performance

(₹ crs)

Particulars	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Revenue (net)	764	1031	1818	2664	3,164	3,474	3,891
% of Revenue		35%	138%	47%	19%	10%	12%
Employees exp	373	492	962	1,495	1,640	1,841	2,062
other expenses	93	148	335	399	456	486	545
TOTAL OPER EXPENDITURE	466	640	1,297	1,894	2,096	2,328	2,607
% of Revenue	61%	62%	71%	71%	66%	67%	67%
EBITDA	297	391	521	770	1,068	1,146	1,284
% Margin	39%	38%	29%	29%	34%	33%	33%
Depreciation	23	25	59	113	118	120	120
Operating Profit	274	367	462	658	950	1,026	1,164
% Margin	36%	36%	25%	25%	30%	30%	30%
Other Income	21	29	40	39	17	15	15
EBIT	295	396	502	697	968	1,041	1,179
Finance Cost	6	5	60	90	78	75	75
EBT	288	390	442	607	890	966	1,104
EBT after exceptional	269	359	442	607	890	966	1,104
Total Tax Expense / (Credit)	36	54	71	120	186	203	232
PAT (Reported)	233	305	371	487	704	763	872
% Margin	31%	30%	20%	18%	22%	22%	22%
EPS - Reported	14.0	18.1	22.2	28.6	41.4	44.8	51.2

Source: Company, Way2Wealth

FINANCIALS & VALUATION

(₹ crs)

Particulars	Q3FY26	Q3FY25	YoY %	Q2FY26	QoQ %	9MFY26	9MFY25	YoY %
Revenue (net)	815	657	24%	781	4%	2,336	1,940	20%
TOTAL INCOME	815	657	24%	781	4%	2,336	1,940	20%
Employees exp	406	383	6%	407	0%	1,209	1,108	9%
other expenses	127	92	38%	102	25%	336	288	17%
TOTAL OPER EXPENDITURE	534	476	12%	509	5%	1,545	1,396	11%
EBITDA	281	181	55%	272	4%	791	544	45%
% Margin	35%	28%		34.8%		34%	28%	
Depreciation	32	28	15%	30	6%	90	84	7%
Operating Profit	249	154	62%	241	3%	701	460	52%
% Margin	31%	23%		31%		30%	24%	
Other Income	6	27	-79%	4	52%	12	36	-66%
EBIT	255	181	41%	245	4%	713	496	44%
Finance Cost	23	21	14%	16	45%	58	69	-16%
EBT	232	160	45%	229	1%	655	427	54%
EBT after exceptional	232	160	45%	229	1%	655	427	54%
Total Tax Expense / (Credit)	46	30	51%	47	-2%	136	88	55%
PAT (Reported)	183	130	41%	181	1%	515	339	52%
% Margin	22%	20%		23%		22%	17%	
EPS - Reported	10.8	7.6	41%	10.6	1%	30	20	52%

Source: Company, Way2Wealth

Disclaimer

Analyst Certification: I, Rupali Singh, the research analyst and author of this report, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s), principally responsible for the preparation of this research report, receives compensation based on overall revenues of the company (Way2Wealth Brokers Private Limited, hereinafter referred to as Way2Wealth) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

It is confirmed that Rupali Singh, the author of this report has not received any compensation from the companies mentioned in the report in the preceding 12 months. Our research professionals are paid in part based on the profitability of Way2Wealth, which include earnings from other business. Neither Way2Wealth nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information contained in this report.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Way2Wealth is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. The contents of this material are general and are neither comprehensive nor appropriate for every individual and are solely for the informational purposes of the readers. This material does not take into account the specific objectives, financial situation or needs of an individual/s or a Corporate/s or any entity/s.

This research has been prepared for the general use of the clients of the Way2Wealth and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient, you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Way2Wealth will not treat recipients as customers by virtue of their receiving this report. The distribution of this document in other jurisdictions may be restricted by the law applicable in the relevant jurisdictions and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The report is based upon information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up to date and it should not be relied upon as such. Way2Wealth or any of its affiliates or employees makes no warranties, either express or implied of any kind regarding any matter pertaining to this report, including, but not limited to warranties of suitability, fitness for a particular purpose, accuracy, timeliness, completeness or non-infringement. We accept no obligation to correct or update the information or opinions in it. Way2Wealth or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. The recipients of this report should rely on their own investigations. In no event shall Way2Wealth be liable for any damages of any kind, including, but not limited to, indirect, special, incidental, consequential, punitive, lost profits, or lost opportunity, whether or not Way2Wealth has advised of the possibility of such damages.

This material contains statements that are forward-looking; such statements are based upon the current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These uncertainties include but are not limited to: the risk of adverse movements or volatility in the securities markets or in interest or foreign exchange rates or indices; adverse impact from an economic slowdown; downturn in domestic or foreign securities and trading conditions or markets; increased competition; unfavorable political and diplomatic developments; change in the governmental or regulatory policies; failure of a corporate event and such others. This is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. No part of this material may be copied or duplicated in any form by any means or redistributed without the written consent of Way2Wealth. In no event shall any reader publish, retransmit, redistribute or otherwise reproduce any information provided by Way2Wealth in any format to anyone. Way2Wealth and its affiliates, officers, directors and employees including persons involved in the preparation or issuance of this report may from time to time have interest in securities / positions, financial or otherwise in the securities related to the information contained in this report.

To enhance transparency, Way2Wealth has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Disclosure of Interest Statement Inventurus Knowledge Solutions Limited (IKS Health) as on 11th February 2026

Name of the Security	Inventurus Knowledge Solutions Limited (IKS Health)
Name of the analyst	Rupali Singh
Analysts' ownership of any stock related to the information contained	NIL
Financial Interest	
Analyst :	Yes (20 shares on 2 nd December 2025)
Analyst's Relative : Yes / No	No
Analyst's Associate/Firm : Yes/No	No
Conflict of Interest	No
Receipt of Compensation	No
Way2Wealth ownership of any stock related to the information contained	NIL
Broking relationship with company covered	NIL
Investment Banking relationship with company covered	NIL

This information is subject to change without any prior notice. Way2Wealth reserves at its absolute discretion the right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, Way2Wealth is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and Enlistment with RAASB/BSE and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.